For the quarter ended December 2022, Eli Lilly (LLY - Free Report) reported revenue of $7.3 billion, down 8.7% over the same period last year. EPS came in at $2.09, compared to $2.49 in the year-ago quarter.
The reported revenue represents a surprise of -0.28% over the Zacks Consensus Estimate of $7.32 billion. With the consensus EPS estimate being $1.83, the EPS surprise was +14.21%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Lilly performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net sales-Basaglar (LY2963016 / Insulin Glargine) - ROW: $70.90 million versus the four-analyst average estimate of $74.47 million. The reported number represents a year-over-year change of -8.4%.
- Revenue -Other Neuroscience- Outside U.S. $15.20 million versus the four-analyst average estimate of $32.44 million.
- Net sales-Cyramza (Ramucirumab /IMC-1121B) - ROW: $185.70 million compared to the $158.27 million average estimate based on four analysts. The reported number represents a change of +4% year over year.
- Net sales-Trulicity (Dulaglutide / GLP-1 Fc / LY2189265) - US: $1.53 billion versus $1.61 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +5.4% change.
- Basaglar (LY2963016 / Insulin Glargine) - Total: $201.70 million versus $205.41 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -16.8% change.
- Cyramza (Ramucirumab /IMC-1121B) -Total: $277.80 million compared to the $249.10 million average estimate based on four analysts. The reported number represents a change of +2.7% year over year.
- Revenue - Diabetes - Other: $27.90 million versus the four-analyst average estimate of $142.34 million.
- Trulicity (Dulaglutide / GLP-1 Fc / LY2189265) -Total: $1.94 billion compared to the $2.08 billion average estimate based on four analysts. The reported number represents a change of +2.8% year over year.
- Jardiance (Empagliflozin/BI 10773)- Total: $612.30 million compared to the $610.59 million average estimate based on four analysts. The reported number represents a change of +41.8% year over year.
- Net sales- Immunology: $933.60 million versus $943.70 million estimated by four analysts on average.
- Olumiant/Baricitinib (LY3009104)/JAK1/JAK2 Inhibitor - Total: $205.80 million versus the four-analyst average estimate of $197.21 million. The reported number represents a year-over-year change of -32.8%.
- Net sales-Taltz (Ixekizumab / LY2439821 / IL-17) - Total: $707.80 million compared to the $743.25 million average estimate based on four analysts. The reported number represents a change of +9.3% year over year.
View all Key Company Metrics for Lilly here>>>
Shares of Lilly have returned -5.7% over the past month versus the Zacks S&P 500 composite's +7.4% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
For the quarter ended December 2022, Eli Lilly (LLY - Free Report) reported revenue of $7.3 billion, down 8.7% over the same period last year. EPS came in at $2.09, compared to $2.49 in the year-ago quarter.
The reported revenue represents a surprise of -0.28% over the Zacks Consensus Estimate of $7.32 billion. With the consensus EPS estimate being $1.83, the EPS surprise was +14.21%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Lilly performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
View all Key Company Metrics for Lilly here>>>
Shares of Lilly have returned -5.7% over the past month versus the Zacks S&P 500 composite's +7.4% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on LLY - FREE